Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
20
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
stocks
Nvidia: Back in business in China; Raising fair value estimate
stocks
Our top ASX picks in every sector
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,816.40 | 58.90 | -0.66% |
CAC 40 | 7,774.85 | 8.64 | 0.11% |
DAX 40 | 24,200.10 | 139.81 | 0.58% |
Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
FTSE 100 | 8,971.03 | 32.71 | 0.37% |
HKSE | 24,517.76 | 72.36 | -0.29% |
NASDAQ | 20,677.80 | 37.47 | 0.18% |
Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
S&P 500 | 6,243.76 | 0.00 | 0.00% |
S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
SSE Composite Index | 3,503.78 | 1.22 | -0.03% |